Falls Church, VA (PRWEB)
June 26, 2017
FDA’s Big 5 Challenges:
Agency Tackles Botox, Cannabis, Opioids, Tobacco Intended Use, Right-to-Try
**An FDAnews Webinar**
July 13, 2017 — 1:30 p.m. – 3:00 p.m. ET
Botox. Cannabis. Opioids. Tobacco intended use. Right-to-try. It’s a regulatory agenda with potentially national, and even global impact.
Drugmakers, food and tobacco processors all stand at risk.
And Donald Trump only multiplies the uncertainties.
Where will President Trump’s newly minted FDA Commissioner, Scott Gottlieb MD, come down on these controversies? What is his staff discussing right now?
FDAnews has enlisted a food and drug law expert with more than 30 years’ experience to bring manufacturers up to speed.
Roseann B. Termini Esq. takes webinar attendees behind the FDA’s closed doors. She’ll dig deep into:
Botox approvals: Black box warnings, patents, scams, Botox® parties, legal implications, state actions
- Marijuana regulation: Likelihood of regulation as a drug, “medical marijuana” and the FDA, synthetic marijuana regulation, state and local actions
- Opioid Task Force: How its actions could affect Rx drugmakers, potential new regulatory initiatives
- The Intended Use Rule: How it might change during the Gottlieb tenure
- Right-to-Try Movement: Gaining momentum or losing steam? And what will be the impact on pharmaceutical regulatory and quality operations?
This session is the first ever to tackle all 5 hot-button issues before the FDA.
Meet the Presenter:
Food and drug law expert Roseann B. Termini Esq. is an author, educator and advocate specializing in direct-to-consumer advertising and corporate accountability. As a lawyer she…